Selank

Selank is a synthetic heptapeptide with anxiolytic and nootropic properties. It is a derivative of the endogenous tetrapeptide tuftsin, involved in immune function and phagocytosis. Selank is not FDA-approved and is currently unregulated, meaning its production and distribution are not subject to the same stringent oversight as pharmaceutical drugs. This lack of regulation necessitates careful consideration by consumers regarding sourcing and quality control. Its current trust score is 62.5/100, earning a grade of C+, based on available research, safety data, and regulatory status.

The purported mechanism of action of Selank is multifaceted, involving modulation of neurotransmitter systems and gene expression. Research suggests it influences the levels of dopamine, serotonin, and norepinephrine in the brain. It is also believed to affect the expression of brain-derived neurotrophic factor (BDNF), a protein crucial for neuronal growth, survival, and synaptic plasticity. Some studies indicate that Selank may have immunomodulatory effects, potentially influencing the balance of T helper cell cytokines. However, the precise mechanisms and the extent of these effects are still under investigation.

The research landscape surrounding Selank is varied, encompassing both preclinical and clinical studies. A total of 11 clinical trials and 134 research papers have been published. Clinical trials have explored Selank's potential applications in various conditions. For example, one completed study investigated the effects of acute exposure to high altitude hypoxia on cognitive function in lowlanders, sponsored by Xijing Hospital. Selank was also included as a comparator in several large Phase 3 trials studying the efficacy of brivaracetam for epilepsy treatment, sponsored by UCB Pharma. Furthermore, studies have explored its use in depression treatment (Universitätsklinikum Hamburg-Eppendorf) and imagery rescripting for fear of failure (University of Social Sciences and Humanities, Warsaw). While these trials provide some insight, further research is needed to establish definitive efficacy for specific indications.

Research papers related to Selank cover a wide range of topics. While some directly investigate the peptide's effects, others mention it in the context of broader scientific investigations. For example, a review article in the *International Journal of Molecular Sciences* cited Selank in the context of exosomal and non-exosomal microRNAs in cancer therapy. Other papers, such as those published in *Cardiovascular Research*, *BMC Plant Biology*, *Scientific Reports*, and *Scientific Reports*, mention Selank in studies related to atrial fibrillation, plant nutrient allocation, biomethane production from food waste, and correlations between urinary perchlorate and liver function indices, respectively. These indirect references highlight the peptide's presence in the scientific literature, even if not as the primary focus of the research.

The safety profile of Selank appears relatively benign based on current data. The FDA adverse event reporting system (FAERS) shows zero total reports and zero classified as serious adverse events associated with Selank. However, the absence of reported adverse events does not guarantee complete safety, especially given the limited scope of clinical trials and the unregulated nature of the peptide.

Due to its unregulated status, Selank is typically used by individuals interested in self-experimentation, nootropics, and alternative health approaches. These users often seek cognitive enhancement, anxiety relief, or immune support. It is important to note that the lack of regulatory oversight means that the quality and purity of Selank products can vary significantly between vendors, posing a potential risk to consumers.

The future of Selank hinges on further research to elucidate its mechanisms of action, establish its efficacy for specific conditions, and determine its long-term safety profile. The regulatory outlook remains uncertain, and the peptide's status could change as more data becomes available.